Cannabidiol - Botanix Pharmaceuticals

Drug Profile

Cannabidiol - Botanix Pharmaceuticals

Alternative Names: BTX 1204; BTX 1308; BTX 1503; BTX 1801; BTX1204 - Atopic dermatitis; BTX1308 - Plaque psoriasis; BTX1503 - Acne; PBX 1308

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Botanix Pharmaceuticals
  • Developer Botanix Pharmaceuticals; University of Queenslands Institute for Molecular Bioscience
  • Class Analgesics; Antiepileptic drugs; Antipsoriatics; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Heart failure therapies; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acne
  • Phase I Atopic dermatitis
  • Preclinical Plaque psoriasis
  • Research Skin disorders

Most Recent Events

  • 23 Jul 2018 Botanix Pharmaceuticals completes a phase Ib trial in Atopic dermatitis in Australia
  • 23 Jul 2018 Botanix Pharmaceuticals plans a phase Ib trial of BTX 1308 for Psoriasis in the third quarter of 2018
  • 23 Jul 2018 Botanix Pharmaceuticals plans a phase II trial of BTX 1204 for Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top